Central Garden & Pet Raises Fiscal 2025 Non-GAAP EPS Outlook;
Margin expansion is being driven by our Cost and Simplicity initiatives and a favorable product mix.
Share
'Fiscal 2025 is tracking ahead of our expectations, reflecting disciplined execution across Team Central,' said Niko Lahanas, CEO of Central Garden & Pet. 'Margin expansion is being driven by our Cost and Simplicity initiatives and a favorable product mix. The organization remains highly aligned and focused on delivering value to our consumers and shareholders.'
Lahanas continued, 'As we look toward the remainder of the fiscal year, we want to emphasize that our fourth quarter is seasonally small, and the operating environment remains dynamic. Our outlook reflects continued uncertainty around evolving consumer demand. We remain focused on executing our strategic priorities, including making targeted investments to fuel long-term growth. These investments are expected to enable us to capitalize on opportunities in both the Pet and Garden segments and further advance our Central to Home strategy.'
This updated outlook reflects anticipated shifts in consumer behavior amid macroeconomic and geopolitical uncertainty, challenges within the brick-and-mortar retail landscape, and the weather variability anticipated for the remainder of the fiscal year. This outlook excludes the potential impact of further changes in tariff rates, as well as any acquisitions, divestitures, or restructuring activities that may arise during the remainder of fiscal 2025, including initiatives under the Cost and Simplicity program.
Central anticipates fiscal 2025 capital expenditures of approximately $60 million.
The Company will provide additional details during its fiscal 2025 third-quarter earnings call scheduled for August 6, 2025.
About Central Garden & Pet
Central Garden & Pet Company (NASDAQ: CENT), (NASDAQ: CENTA) understands that home is central to life and has proudly nurtured happy and healthy homes for over 45 years. With fiscal 2024 net sales of $3.2 billion, Central is on a mission to lead the future of the pet and garden industries. The Company's innovative and trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier, and communities grow stronger. Central is home to a leading portfolio of more than 65 high-quality brands including Amdro ®, Aqueon ®, Cadet ®, C&S ®, Farnam ®, Ferry-Morse ®, Four Paws ®, Kaytee ®, Nylabone ® and Pennington ®, strong manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central is based in Walnut Creek, California, with more than 6,000 employees, primarily across North America. Visit www.central.com to learn more.
Safe Harbor Statement
The statements contained in this release which are not historical facts, including statements concerning consumer demand, the impact of investments on long-term growth, the expected impact of tariffs, anticipated capital expenditures, and updated earnings guidance for fiscal 2025, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. All forward-looking statements are based upon Central's current expectations and various assumptions. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release including, but not limited to, the following factors:
economic uncertainty and other adverse macroeconomic conditions, including a potential recession;
impacts of tariffs or a trade war;
risks associated with international sourcing, including from China;
fluctuations in energy prices, fuel and related petrochemical costs;
declines in consumer spending and the associated increased inventory risk;
seasonality and fluctuations in our operating results and cash flow;
adverse weather conditions and climate change;
the success of our Central to Home strategy and our Cost and Simplicity program;
fluctuations in market prices for seeds and grains and other raw materials, including the impact of significant declines in grass seed market prices on our inventory valuation;
risks associated with new product introductions, including the risk that our new products will not produce sufficient sales to recoup our investment;
dependence on a small number of customers for a significant portion of our business;
consolidation trends in the retail industry;
supply shortages in pet birds, small animals and fish;
potential credit risk associated with certain brick and mortar retailers in the pet specialty segment;
reductions in demand for our product categories;
competition in our industries;
continuing implementation of an enterprise resource planning information technology system;
regulatory issues;
potential environmental liabilities;
access to and cost of additional capital;
the impact of product recalls;
risks associated with our acquisition strategy, including our ability to successfully integrate acquisitions and the impact of purchase accounting on our financial results;
potential goodwill or intangible asset impairment;
the potential for significant deficiencies or material weaknesses in internal control over financial reporting, particularly of acquired companies;
our dependence upon our key executives;
our ability to recruit and retain members of our management team and employees to support our businesses;
potential costs and risks associated with actual or potential cyberattacks;
our ability to protect our trademarks and other proprietary rights;
litigation and product liability claims;
the impact of new accounting regulations and the possibility our effective tax rate will increase as a result of future changes in the corporate tax rate or other tax law changes;
potential dilution from issuance of authorized shares; and
the voting power associated with our Class B stock.
These and other risks are described in greater detail in Central's Annual Report on Form 10-K for the fiscal year ended September 28, 2024, filed with the Securities and Exchange Commission on November 27, 2024. Central assumes no obligation to publicly update these forward-looking statements to reflect new information, future events, or any other development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Stock Index Futures Plunge on Trump's Tariffs, U.S. Jobs Report in Focus
September S&P 500 E-Mini futures (ESU25) are down -0.93%, and September Nasdaq 100 E-Mini futures (NQU25) are down -1.03% this morning as U.S. President Donald Trump's sweeping import tariffs fueled concerns about the outlook for economic growth. Late on Thursday, President Trump signed an executive order imposing tariffs between 10% and 41% on U.S. imports from foreign nations. Those hardest hit include Switzerland with a 39% tariff, Taiwan with a 20% tariff, and Canada, which is subject to a 35% levy on goods that do not comply with the U.S.-Mexico-Canada Agreement. Meanwhile, the U.S. president granted a one-week delay to trading partners that had received letters, with the exception of Canada. The average U.S. tariff would increase to 15.2% if the announced rates are implemented, according to Bloomberg Economics, up from 13.3% previously and well above the 2.3% level in 2024 before Trump took office. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? This High-Yield Dividend Stock Just Slashed Its Payout. Is It Time to Sell Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Also weighing on stock index futures, shares of (AMZN) slumped over -7% in pre-market trading after the tech and online retailing giant projected weaker-than-expected Q3 operating income. Investor focus now turns to the key U.S. payrolls report. In yesterday's trading session, Wall Street's major indices closed lower. Align Technology (ALGN) plummeted over -36% and was the top percentage loser on the S&P 500 after the company posted downbeat Q2 results and issued below-consensus Q3 revenue guidance. Also, Arm Holdings (ARM) plunged more than -13% and was the top percentage loser on the Nasdaq 100 after the chip designer provided soft FQ2 adjusted EPS guidance. In addition, pharmaceutical stocks slumped after President Trump demanded that drugmakers slash U.S. prices, with Bristol-Myers Squibb (BMY) sliding over -5% and Merck & Co. (MRK) falling more than -4%. On the bullish side, Meta Platforms (META) surged over +11% and was the top percentage gainer on the Nasdaq 100 after the maker of Facebook and Instagram posted upbeat Q2 results and issued strong Q3 revenue guidance. Data from the U.S. Department of Commerce released on Thursday showed that the core PCE price index, a key inflation gauge monitored by the Fed, came in at +0.3% m/m and +2.8% y/y in June, compared to expectations of +0.3% m/m and +2.7% y/y. Also, U.S. June personal spending rose +0.3% m/m, weaker than expectations of +0.4% m/m, and personal income rose +0.3% m/m, stronger than expectations of +0.2% m/m. In addition, the U.S. employment cost index rose +0.9% q/q in the second quarter, stronger than expectations of +0.8% q/q. Finally, the number of Americans filing for initial jobless claims in the past week rose +1K to 218K, compared with the 222K expected. 'Inflation remains sticky and justifies the Fed's decision to keep interest rates unchanged at Wednesday's meeting,' said Clark Bellin at Bellwether Wealth. 'The stock market doesn't need rate cuts in order to move higher and has already posted strong gains so far this year without any rate cuts.' Meanwhile, U.S. rate futures have priced in a 61.0% probability of no rate change and a 39.0% chance of a 25 basis point rate cut at the next FOMC meeting in September. Today, all eyes are focused on the U.S. monthly payroll report, which is set to be released in a couple of hours. Economists, on average, forecast that July Nonfarm Payrolls will come in at 106K, compared to the June figure of 147K. Investors will also focus on U.S. Average Hourly Earnings data. Economists expect July figures to be +0.3% m/m and +3.8% y/y, compared to the previous numbers of +0.2% m/m and +3.7% y/y. The U.S. Unemployment Rate will be reported today. Economists forecast that this figure will creep up a tick to 4.2% in July from 4.1% in the prior month. The U.S. ISM Manufacturing PMI and the S&P Global Manufacturing PMI will be closely watched today. Economists expect the July ISM Manufacturing PMI to be 49.5 and the S&P Global Manufacturing PMI to be 49.7, compared to the previous values of 49.0 and 52.9, respectively. U.S. Construction Spending data will be released today. Economists estimate this figure will be unchanged m/m in June, compared to -0.3% m/m in May. The University of Michigan's U.S. Consumer Sentiment Index will be released today as well. Economists expect the final July figure to be revised slightly higher to 62.0 from the preliminary reading of 61.8. On the earnings front, notable companies like Exxon Mobil (XOM), Chevron (CVX), Enbridge (ENB), and Colgate-Palmolive (CL) are slated to release their quarterly results today. According to Bloomberg Intelligence, companies in the S&P 500 are expected to post an average +4.5% increase in quarterly earnings for Q2 compared to the previous year, exceeding the pre-season estimate of +2.8%. In the bond market, the yield on the benchmark 10-year U.S. Treasury note is at 4.384%, up +0.55%. The Euro Stoxx 50 Index is down -1.84% this morning as sentiment took a hit following U.S. President Donald Trump's announcement of steeper tariffs on dozens of countries. Healthcare stocks led the declines on Friday after Trump sent letters to 17 major pharmaceutical firms, including Novo Nordisk and Sanofi, urging them to reduce drug prices for U.S. consumers. The benchmark index is on track to post its biggest weekly drop since early April. Preliminary data from Eurostat released on Friday showed that the Eurozone's annual inflation rate held steady at the European Central Bank's target in July, reinforcing the argument for policymakers to keep their key interest rate unchanged next month. Separately, a survey showed that Eurozone manufacturing edged closer to stabilization in July, as factory activity shrank at the slowest rate in three years, despite a decline in new orders and a moderation in output growth. Meanwhile, Switzerland was among the countries most affected by the latest round of tariff announcements as it now faces a 39% tariff on its exports to the U.S. The country's federal council stated it remained committed to pursuing a negotiated solution with the U.S. In corporate news, Davide Campari-Milano NV ( climbed over +8% after reporting a higher Q2 operating profit. Eurozone's Manufacturing PMI, Eurozone's CPI (preliminary), and Eurozone's Core CPI (preliminary) data were released today. Eurozone's July Manufacturing PMI came in at 49.8, in line with expectations. Eurozone's July CPI rose +2.0% y/y, stronger than expectations of +1.9% y/y. Eurozone's July Core CPI rose +2.3% y/y, in line with expectations. Asian stock markets today settled in the red. China's Shanghai Composite Index (SHCOMP) closed down -0.37%, and Japan's Nikkei 225 Stock Index (NIK) closed down -0.66%. China's Shanghai Composite Index closed lower today as weak economic data from the country and concerns over global trade following U.S. President Donald Trump's new tariffs weighed on sentiment. The benchmark index notched its first weekly loss in six weeks. A private sector survey released on Friday showed that China's manufacturing activity unexpectedly slipped back into contractionary territory in July, as weakening new business growth prompted factories to cut back production. The reading, coupled with Thursday's official survey, signals weak growth momentum at the start of the third quarter, following solid growth in the first half of the year. Chinese leaders at the much-anticipated Politburo meeting signaled on Wednesday that they would hold off on introducing major stimulus for now, but vowed to more effectively implement existing pro-growth measures. Meanwhile, U.S. President Donald Trump announced higher tariffs on dozens of trading partners. ANZ economists said in a note on Friday that 'the U.S. deals with other economies will also affect China's trade outlook.' Investor focus is now on whether the U.S.-China tariff truce will be extended after U.S. and Chinese officials wrapped up their latest round of trade talks in Stockholm earlier this week, with U.S. President Donald Trump set to make the final decision. U.S. Treasury Secretary Scott Bessent said on Thursday that the U.S. sees the framework of a trade deal with China taking shape, but it is 'not 100% done.' In corporate news, Sinopec slumped over -5% after the nation's largest oil refiner projected a 40% to 44% drop in first-half profit. The Chinese July Caixin Manufacturing PMI came in at 49.5, weaker than expectations of 50.2. Japan's Nikkei 225 Stock Index closed lower today, dragged down by weakness in the technology sector. Chip stocks led the declines on Friday, with Tokyo Electron plunging over -18% after the chip equipment maker reported disappointing Q1 results and cut its full-year guidance. The benchmark index ended the week lower. Also, shortly before Asian markets opened, U.S. President Donald Trump announced new tariff rates on dozens of trading partners, further dampening sentiment. In addition, investors digested weak economic data. A private sector survey released on Friday showed that Japan's manufacturing activity contracted in July after stabilizing in the prior month, as subdued demand dragged production back into contraction. However, the majority of the survey data was gathered prior to last week's announcement of the U.S.-Japan trade deal. As the trade agreement with Washington takes effect, 'it will be important to see if this will translate into greater client confidence and improved sales in the months ahead,' said Annabel Fiddes, economics associate director at S&P Global Market Intelligence. Meanwhile, Japan's top trade negotiator Ryosei Akazawa said on Friday that the country will continue to push the U.S. to implement the agreed reduction in automobile and auto parts tariffs to 15% from 25%. In other news, the Kyodo news agency reported on Friday that a Japanese labor ministry panel plans to propose a roughly 6% increase in the national average minimum wage for this fiscal year, marking the largest such rise since at least 2002. The Nikkei Volatility Index, which takes into account the implied volatility of Nikkei 225 options, closed up +3.74% to 23.29. The Japanese July au Jibun Bank Manufacturing PMI stood at 48.9, stronger than expectations of 48.8. The Japanese June Unemployment Rate was 2.5%, in line with expectations. Pre-Market U.S. Stock Movers (AMZN) slumped over -7% in pre-market trading after the tech and online retailing giant projected weaker-than-expected Q3 operating income. Apple (AAPL) rose more than +1% in pre-market trading after the iPhone maker posted its fastest quarterly revenue growth in more than three years, easily beating analysts' estimates. Reddit (RDDT) surged over +16% in pre-market trading after the social media company posted upbeat Q2 results and issued above-consensus Q3 revenue guidance. You can see more pre-market stock movers here Today's U.S. Earnings Spotlight: Friday - August 1st Exxon Mobil (XOM), Chevron (CVX), Enbridge (ENB), Colgate-Palmolive (CL), Ares Management (ARES), Mitsui & Company (MITSY), Regeneron Pharma (REGN), WW Grainger (GWW), Dominion Energy (D), Imperial Oil (IMO), Kimberly-Clark (KMB), Cboe Global (CBOE), TELUS (TU), Fortis Inc (FTS), Church&Dwight (CHD), T Rowe (TROW), LyondellBasell Industries (LYB), Brookfield Renewable (BEP), nVent Electric (NVT), Franklin Resources (BEN), RBC Bearings (RBC), Magna Intl (MGA), EchoStar (SATS), Avantor (AVTR), Fluor (FLR), Ingredion (INGR), Oshkosh (OSK), IES Holdings (IESC), Piper Sandler (PIPR), Brookfield Business (BBU), Brightspring Health Services (BTSG), TransAlta Corp (TAC), Cinemark (CNK), Avient Corp (AVNT), Newell Brands (NWL), Arbor (ABR), Insperity (NSP), Patria Investments (PAX), WisdomTree (WT), Perella Weinberg Partners (PWP), Xenia Hotels & Resorts Inc (XHR), Dorian LPG Ltd (LPG), Interface (TILE), TELUS International (TIXT), Iradimed Co (IRMD), AdvanSix (ASIX), Fulgent Genetics (FLGT), Marcus (MCS), Butterfly Network (BFLY), Airsculpt Technologies (AIRS), Johnson Outdoors (JOUT), Ocugen (OCGN), AG Mortgage Investment (MITT), Escalade (ESCA). On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Forbes
11 minutes ago
- Forbes
AMD Stock To $330?
Could AMD stock (NASDAQ:AMD) reach $330 in the next two years? There's a good chance of this happening. How? Consider this, just about four months ago, at the end of April 2025, AMD stock was trading at around $80 levels and has seen a massive rally to close to $180 per share currently. Looking at the valuations, AMD stock trades at about 55x trailing earnings and just about 45x projected 2025 earnings. Is this pricey? No. Especially if you consider AMD's steadily expanding earnings, growing share of the CPU market, and most importantly, the long-growth runway for the artificial intelligence market. In the scenario below, we use AMD's revenues, profitability, and valuation multiples to demonstrate a potential path to a $ 300-plus stock price in the near future. AMD's GPUs Can Drive Revenue AMD's revenues have risen considerably from $6.7 billion in 2019 to about $26 billion in 2024, an annual growth of over 31%, and the momentum can hold up. Consensus projects a close to 25% growth for 2025. However, there is a real opportunity for AMD to grow its sales at an average annual rate of close to 35% for the next two years, led by growth in accelerated computing space and its new GPUs. Its revenues could move from an estimated $32 billion in FY'25 to around $58.3 billion by FY'27, or an over 80% increase. Several trends could drive this continued growth. Separately, if you are looking for potential gains with reduced volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative—having surpassed the performance of the S&P 500 and produced returns of over 91% since its inception. More capable AI chips from AMD: AMD is likely to see strong tailwinds from the generative AI trend, as graphics processing units have become the de facto chips for running AI-related workloads. To be sure, Nvidia makes the best AI chips in the market and has a hardware and software ecosystem that is well entrenched with big cloud providers. However, there remains a considerable opportunity for AMD. At its AI Day earlier this year, AMD unveiled its latest MI350 lineup, which it says will deliver 4x the AI compute performance of its predecessor. Beyond hardware, AMD is building out its AI software and systems stack. These moves could also strengthen AMD's ROCm software stack, which takes an open-source, standards-based approach, a contrast to Nvidia's proprietary CUDA ecosystem. AMD appears confident about its AI products. Earlier this week, there were reports that the company would bump up pricing on its Instinct MI350 AI GPUs from $15,000 to $25,000 - a 70% hike (related: See how artificial general intelligence can 2x Nvidia stock). Inference Can Drive AI Market Share: As a larger mix of AI workloads will shift to inference - essentially using the built models in real-world applications - where efficiency and cost matter more than brute force computing power, AMD could see gains. Costs are also becoming a concern for end-customers of AI chips, as Nvidia's strong pricing power has pushed its net margins above 50% in recent quarters. This could benefit AMD, as customers look for more affordable alternatives to build out data centers quickly. This trend is already playing out. For example, Oracle chose AMD's accelerated computing chips to power its latest super cluster for high-intensity AI workloads, after testing showed AMD's GPUs delivered low latency and strong performance at a competitive price. Even after the reported price hike, AMD's MI350 would still undercut Nvidia's entry-level Blackwell B200, while offering superior specs (related: AMD Stock's Big AI Opportunity Is Taking Shape). Overall, there is plenty of room for growth. AMD estimates that the market for AI accelerator chips will reach approximately $400 billion in 2027. HSBC projects that AMD could see AI-related sales exceed $15 billion by 2026, compared to over $5 billion in 2024. The large market size and continued momentum should make a 35%+ growth in total revenues over the next two years a real possibility. Higher-End Products Can Drive Margins Combine this robust revenue growth with the fact that AMD's adjusted net margins (net income, or profits after all expenses and taxes, calculated as a percent of revenues) are on an improving trajectory - they grew from levels of about 11% in FY'19 to over 21% in FY'24 as the company sees better economies of scale and a more favorable product mix skewed toward complex data center products. Margins could potentially trend still higher to levels of about 25%, as AMD sees higher GPU sales with higher economies of scale, improving its fixed cost absorption. Now, combining 25% adjusted net margins, with about $58 billion in revenue, would translate into earnings of about $14.5 billion. That's a roughly 2.7x increase from levels seen in 2024. Strong Results Mean A Smaller Contraction In Earnings Multiples Now, if earnings grow 2.7x, the price-to-earnings multiple will shrink by 2.7x to levels of about 21x, assuming the stock price stays the same. But that's exactly what AMD investors are betting will not happen. If earnings expand 2.7x over the next few years, instead of the P/E shrinking from a figure around 55x now to about 21x, a scenario where the PE metric stays at about 40x looks quite likely, as stronger growth and expanding margins give investors more confidence about AMD's future. This would make the growth of AMD stock to levels of close to $330 within the next few years a real possibility. So what about the time horizon for this high-return scenario? While our above example illustrates a roughly two-year time frame, in practice, it won't make much difference whether it takes two years or three, as long as AMD is on this revenue expansion trajectory, with margins holding up, the stock price could respond similarly. While AMD stock may have considerable potential, investing in individual stocks can be risky. As an alternative, the Trefis Reinforced Value (RV) Portfolio has outperformed its all-cap stocks benchmark (combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to produce strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid- and small-cap RV Portfolio stocks provided a responsive way to make the most of upbeat market conditions while limiting losses when markets head south, as detailed in RV Portfolio performance metrics.
Business Wire
12 minutes ago
- Business Wire
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead's investigational cardiometabolic candidates in Greater China. Under the terms, Sanofi will acquire rights to develop and commercialize investigational plozasiran, Arrowhead's first-in-class RNA interference (RNAi) therapeutic candidate designed to reduce production of apolipoprotein C-III (APOC3) as a potential treatment for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), in Greater China. Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, which was previously granted rights to investigational plozasiran in Greater China Share Visirna has completed a Phase 3 clinical trial (CTR20231418/NCT05902598) of investigational plozasiran in Chinese patients with familial chylomicronemia syndrome (FCS), which successfully met its primary efficacy endpoint and all key secondary endpoints. Visirna subsequently submitted a New Drug Application (NDA) for plozasiran to the National Medical Products Administration (NMPA) in China for the treatment of FCS and received official acceptance in January 2025. Plozasiran has also been granted Breakthrough Therapy Designation in the treatment of patients with FCS and Priority Review Designation by the China NMPA. 'When we founded Visirna in 2022, we believed that Greater China represented an important potential future market for multiple programs in Arrowhead's pipeline of investigational RNAi-based candidates for cardiometabolic diseases,' said Christopher Anzalone, Ph.D., Arrowhead's President and CEO. 'The team at Visirna understand the intricacies of China's clinical, regulatory, and commercial environment and have done impressive work moving plozasiran through clinical studies and into the regulatory submission and review process. We now look forward to working with Sanofi and believe they are extremely well positioned as a global company with a strong presence in China.' Wayne Shi, President, Sanofi Greater China, added, 'We are pleased to have concluded this agreement to enable us to advance plozasiran in Greater China where Sanofi has deep roots and a proud heritage of serving people living with a wide range of diseases. Plozasiran has shown considerable potential in studies across diverse patient populations where serious illness is caused by elevated triglycerides. With our strong presence in China's cardiometabolic field, we now look forward to bringing it forward to address unmet need.' Upon closing of the Asset Purchase Agreement, Visirna will receive an upfront payment of $130 million from Sanofi. In addition, Visirna will be eligible to receive further milestone payments of up to $265 million upon approval of plozasiran across various indications in mainland China. Arrowhead is further eligible to receive royalties on net commercial product sales in Greater China as part of the Arrowhead-Visirna license which was assigned in part to Sanofi. Gibson, Dunn & Crutcher LLP and Sidley Austin LLP are serving as legal advisors to Arrowhead. About Plozasiran Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism. APOC3 increases triglyceride levels in the blood by inhibiting breakdown of TRLs by lipoprotein lipase and uptake of TRL remnants by receptors in the liver. The goal of treatment with plozasiran is to reduce the level of APOC3, thereby reducing triglycerides and restoring lipids to more normal levels. In multiple clinical studies, investigational plozasiran has demonstrated reductions in triglycerides and multiple atherogenic lipoproteins in patients with familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (SHTG), and mixed hyperlipidemia. Plozasiran has been generally well tolerated to date with treatment emergent adverse events reported that generally reflect the comorbidities and underlying conditions of the study populations. Across clinical studies and study populations, the most frequently reported treatment emergent adverse events for the 25 mg dose that is proposed for marketing approval were COVID-19, upper respiratory tract infection, headache, Type 2 diabetes mellitus, and abdominal pain. Plozasiran is being investigated in the SUMMIT program of clinical studies, which includes the PALISADE Phase 3 study in patients with FCS, the SHASTA Phase 2 and Phase 3 studies in patients with SHTG, and the MUIR Phase 2 and Phase 3 studies in patients with mixed hyperlipidemia. Plozasiran in the treatment of patients with FCS has been granted Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation by the U.S. Food and Drug Administration and Orphan Medicinal Product Designation by the European Medicines Agency. Investigational plozasiran has been submitted for marketing authorization in treatment of FCS to multiple global regulatory authorities but has not been reviewed or approved to treat any disease. About Visirna Therapeutics Visirna Therapeutics was founded in 2022 as a majority owned subsidiary of Arrowhead Pharmaceuticals. Headquartered in China with a global perspective, Visirna strives to emerge as a frontrunner in the advancement of siRNA therapeutics. The existing product portfolio comprises clinical stage siRNA candidates with a focus on cardiovascular/metabolic, and auto-immune ailments. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as 'may,' 'will,' 'expect,' 'believe,' 'anticipate,' 'hope,' 'intend,' 'plan,' 'project,' 'could,' 'estimate,' 'continue,' 'target,' 'forecast' or 'continue' or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.
